The outcome of the first steroid treatment course was prospectively studied in a regional cohort of 196 patients with Crohn's disease diagnosed [1979][1980][1981][1982][1983][1984][1985][1986][1987] (Gut 1994; 35: 360-362) resection before glucocorticoid treatment. Table  I 
resection before glucocorticoid treatment. Table  I shows the median age, sex, and extent of Crohn's disease at diagnosis. The median observation time was 3-4 years (0-9). Follow up rate was 100%.
Steroid treatment response was assessed at day 30 after start of treatment and 30 days after treatment has been stopped. Extent of disease, clinical symptoms, and paraclinical data as s-haemoglobin, leucocyte count, erythrocyte sedimentation rate (ESR), plasma albumin, and orosomucoid were recorded when the first steroid course was started.
Prednisolone treatment was given orally, initially in a dose of approximately 1 mg/kg body weight per day, reduced within weeks to a maintenance dose of 10-15 mg and kept at that level for 3-5 months. The duration of prednisolone treatment lasted less than one year in 95 (87%) ofthe 109 patients, (median 84 days; range 5-299). Fourteen patients (13%) had more than one year of steroid treatment (median 691; range 408-1252).
Although steroid treatment has been proved effective'2 and is generally accepted as the preferable medical treatment in acute, active Crohn's disease, not all patients benefit from such treatment. Some of those who benefit seem to relapse immediately after the treatment has finished. The frequency of steroid resistance and dependency is, however, not well known. 3 The aim of this study was, from a regional, unselected group x'=2-1, df=4, p=0-7.
Frequency ofglucocorticoid resistance and dependency in Crohn's disease Figure 1 shows the immediate outcome within 30 days of steroid treatment. In all 52 (48%) of the patients had achieved a complete clinical remission, 35 (32%) partial remission, and 22 (20%) worsened or were unchanged. No significant differences in immediate outcome were found between patients with disease localisation in small bowel only, large bowel only, and combined localisation (Table II) . Figure 2 shows the prolonged outcome in patients who improved immediately. Twenty eight patients (54%) of those who went into total remission within 30 days also remained free of symptoms 30 days after treatment finished, whereas 24 (46%) patients relapsed. Of these, six could not be withdrawn from treatment and continued receiving steroid treatment for more than one year. Of the patients who improved without reaching complete remission during steroid treatment, 20 (57%) remained improved after treatment finished, while 15 patients (43%) relapsed or could not be withdrawn without recurrence within one year of steroid treatment.
The treatment outcomes can then be summarised as: prolonged steroid response in 44% of the patients, steroid dependency in 36%, and steroid resistance in 20% of the patients. Table III shows the length of steroid treatment in the different outcome groups. Of the nonresponders to steroid treatment, 59% were operated on as a direct consequence of medical treatment failure, as was 26% of the steroid dependent patients (Table IV) . No significant difference in operation rates during the first and second year after treatment was seen between steroid responders, dependents, and nonresponders. 10 An immediate response with systemic steroid treatment of 80 per cent is in agreement with results obtained from controlled trials,' 2 whereas the finding that 36% of all patients treated emerged to be steroid dependent has to our knowledge not previously been shown. According to the treatment policy in our centre, prednisolone treatment has almost exclusively been given orally and only occasionally intravenously. No controlled data pointing to a better effect of glucocorticoids given parenterally rather than perorally exist, assuming the patient has a normal gastric emptying. Our regional patients are referred to one of the gastroenterological departments in the area for treatment and follow up from diagnosis. The very complicated cases suffering from maltreatment or no treatment, as are seen from referral centres are thus avoided. Prediction of response was not possible by either clinical or paraclinical parameters, thus this study is in agreement with the GETAID study. That study however with somewhat different criteria for disease activity, found a higher rate of complete remission of 92% although only endoscopic remission in 29% of the patients."
In conclusion, our analysis of the outcome of the first glucocorticoid treatment course in a regional cohort of 109 patients with Crohn's disease showed that (a) 20 per cent of the patients did not respond at all; (b) although initially responding, 36 per cent of the patients were found to relapse within one month after treatment had stopped or at dose reduction; (c) the outcome of steroid treatment was not correlated with any available clinical or paraclinical characteristics seen before treatment.
